Abstract. MicroRNAs (miRs) are a class of short and non-coding RNA molecules, which function as either oncogenes or tumor suppressors in the development of various human cancers, including nasopharyngeal carcinoma (NPC). The aim of the present study was to investigate the expression of miR-133b in NPC tissue samples, as compared with adjacent normal tissues, and to examine its roles and underlying mechanisms. Analysis using reverse transcription-quantitative polymerase chain reaction demonstrated that miR-133b was downregulated in NPC tissue samples, as compared with adjacent tissues. In vitro experiments using NPC cell lines transfected with miR-133b mimics or antisense oligonucleotides further demonstrated that the overexpression of miR-133b mimics impaired, whereas knockdown of its expression promoted, the proliferation of NPC cells. Sphingosine-1-phosphate receptor 1 (S1PR1) was predicted to be a target of miR-133b. Luciferase reporter assays showed that miR-133b inhibited the protein expression of S1PR1 by targeting its 3'-untranslated region. Furthermore, western blot analysis demonstrated that miR-133B altered the regulation of the signal transducer and activator of transcription-3 (STAT3) signaling pathway and the expression of downstream proteins in NPC cells. Therefore, the results of the present study suggested that a previously unknown miR-133b/S1PR1 molecular network may regulate NPC progression.
Introduction
Nasopharyngeal carcinoma (NPC), which has an incidence of 2.8/100,000 per year in men and 1.9/100,000 per year in women, is the most commonly diagnosed head and neck cancer in Southern China (1) . NPC has previously been associated with Epstein-Barr virus infection, tobacco consumption and various genetic alterations (2, 3) . Furthermore, it has been suggested that microRNAs (miRNAs), which are a class of non-coding RNA molecules, 18-25 nucleotides in length, may have important roles in the carcinogenesis of NPC (4) . In previous studies, the expression of several miRNAs, including miR-29c, miR-372, miR-214 and the let-7 family, has been detected in NPC samples and their roles elucidated (5) (6) (7) (8) . Therefore, regulation of miRNAs may be considered a potential novel strategy for the diagnosis and treatment of patients with NPC.
miR-133b has been identified as a tumor suppressor in numerous types of human cancer (9) ; miR-133b is often downregulated in gastric cancer and its overexpression has been shown to reduce the metastatic potential of gastric cancer cells (10, 11) . In addition, miR-133b has been shown to be downregulated in colorectal cancer tissues, as compared with adjacent tissues (12) , and has been found to inhibit the proliferation of colon cells by suppressing the TATA box-binding protein-like protein 1 (TBPL1) (12) . Furthermore, miR-133b has been shown to inhibit the proliferation, migration and invasion of osteosarcoma cells, and promote their apoptosis (13) . In a previous study, serum levels of miR-133b were able to predict the prognosis of patients with osteosarcoma (14) . However, to the best of our knowledge, the expression status and clinical significance of miR-133b in NPC have yet to be investigated. The present study aimed to investigate the expression levels of miR-133b in NPC tissue samples, as compared with adjacent normal tissues. Furthermore, its roles and underlying mechanisms, including its effects on cell proliferation, were investigated.
Materials and methods
Tissue samples. A total of 23 paired NPC and adjacent normal specimens were collected from 23 male patients undergoing routine therapeutic surgery at the Huaihe Hospital (Kaifeng, China) between October 2012 and October 2014. The age range of the patients was 15 to 28-years-old. Written informed consent was obtained from all patients. All tissue samples were flash-frozen in liquid nitrogen immediately following collection and stored at -80˚C until experimentation. The present study was approved by the institutional review board of Huaihe Hospital.
Cell culture. The NPC cell lines, CNE2 and HONE1, were obtained from the Chinese Academy of Sciences Cell Bank (Shanghai, China). The cells were cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA), supplemented with 10% fetal bovine serum (Merck Millipore, Wanchai, Hong Kong, China). The cultures were maintained at 37˚C in a humidified atmosphere containing 5% CO 2 .
Transient transfection. The CNE2 and HONE1 cells were transfected with miR-133b mimics, miR-133b antisense or negative control (NC; all Genepharm, Inc., Sunnyvale, CA, USA) for 24 h at room temperature using Lipofactamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Inc., Waltham, MA, USA), according to the manufacturer's protocol.
RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA from the patient tissues and CNE2 and HONE1 cell lines was extracted using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific), according to the manufacturer's protocol. The RNA was purified by treatment with PureLink ® DNase Set (Thermo Fisher Scientific) and 20 µl RNA was reverse transcribed into cDNA using the Reverse Transcription System (Promega Corporation, Madison, WI, USA). The expression levels of hsa-miR-133b were determined using the TaqMan ® MicroRNA assay (Applied Biosystems; Thermo Fisher Scientific, Inc.) and the LightCycler ® 480 instrument (Roche Diagnostics, Basel, Switzerland). The primer sequences were as follows: miR-133b forward, 5'-AAA GGA CCC CAA CAA CCA GCA A-3' and reverse, 5'-TTG CTG GTT GTT GGG GTC CTT T-3'; and U6 small nuclear (sn)RNA forward, 5'-CTC GCT TCG GCA GCA CAT ATA CT-3' and reverse, 5'-ACG CTT CAC GAA TTT GCG TGTC-3' (Biosune Biotechnology Co., Shanghai, China). U6 snRNA was used as an internal control for normalization and quantification of the miR-133b expression levels using the 2 -ΔΔCq method (15) . In order to determine the mRNA expression levels of B-cell lymphoma-2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and cellular inhibitor of apoptosis-2 (c-IAP2), qPCR was performed using the SYBR Green Master Mix (Thermo Fisher Scientific) and the LightCycler ® 480 instrument, according to the manufacturer's protocols. The PCR cycling conditions included an initial holding period at 95˚C for 5 min, followed by 45 cycles of 94˚C for 5 sec and 60˚C for 35 sec. The primer sequences were as follows: Bcl-2 forward, 5'-GGT GGG GTC ATG TGT GTGG-3' and reverse, 5'-CGG TTC AGG TAC TCA GTC ATC C-3'; Mcl-1 forward, 5'-TGC TTC GGA AAC TGG ACA TCA-3' and reverse, 5'-TAG CCA CAA AGG CAC CAA AAG-3'; c-IAP2 forward, 5'-AAG CTA CCT CTC AGC CTA CTT T-3' and reverse, 5'-CCA CTG TTT TCT GTA CCC GGA-3'; and β-actin forward, 5'-CAT GTA CGT TGC TAT CCA GGC-3' and reverse, 5'-CTC CTT AAT GTC ACG CAC GAT-3' (Biosune Biotechnology Co.). The β-actin gene was used as an internal control for normalization and quantification of the relative mRNA expression levels using the 2 -ΔΔCq method (15) . The RT-qPCR data were analyzed using the LightCycler ® 480 software, version 1.5.0 (Roche Diagnostics). 
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miR-133b target predictions.
The putative targets of miR-133b were predicted using miRWalk software, release 2.0 (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/). The algorithm produced a list of target genes for miR-133b by searching for the presence of conserved 7-mer and 8-mer sites matching the seed region of miR-133b.
Western blotting. The NPC cells were harvested and lysed using ice-cold lysis buffer [50 mM Tris-HCl, pH 6.8, 5% 2-mercaptoethanol, 2% w/v sodium dodecyl sulfate (SDS), 10% glycerol; Biosune Biotechnology Co.]. Following centrifugation at 20,000 x g for 10 min at 4˚C, the proteins in the supernatants were quantified using a Bicinchoninic Acid Assay kit (Pierce Biotechnology Inc., Rockford, IL, USA). The proteins were separated by 10% SDS-polyacrylamide gel electrophoresis, and transferred to a nitrocellulose membrane (GE Healthcare Life Sciences, Chalfont, UK). After blocking the membrane with 10% non-fat milk in phosphate-buffered saline, the membranes were incubated overnight at 4˚C with the following primary antibodies: Rabbit anti-human sphingosine-1-phosphate receptor 1 (S1PR1) polyclonal antibody (1:1,000; sc-25489; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), goat anti-human phosphorylated signal transducer and activator of transcription 3 (p-STAT3) polyclonal antibody (1:500; sc-21876; Santa Cruz Biotechnology), rabbit anti-human total STAT3 polyclonal antibody (1:2,000; sc-482; Santa Cruz Biotechnology) and anti-rabbit IgG (1:2,000; sc-2491; Santa Cruz Biotechnology), Anti-Mouse IgG1 VHH Single Domain Antibody (1:1,000; ab193651; Abcam, Cambridge, UK) and mouse anti-goat IgG (1:2,000; sc-2489; Santa Cruz Biotechnology) for 2 h at 25˚C. The antibody complexes were detected using the SuperSignal West Pico Chemiluminescent Substrate kit (Pierce Biotechnology), according to manufacturer's protocol. The protein expression levels of S1PR1 and STAT3 were normalized to those of GAPDH, using Quantity One software, version 4.62 (Bio-Rad Laboratories, Inc.).
Luciferase reporter assays. Total cDNA from CNE2 cells was used to amplify the 3'-untranslated region (UTR) of S1PR1 by PCR. The primers used were as follows: Forward, 5'-CTC TGT ATG ACT CTA ATA-3' and reverse, 5'-GAC CGT CGA TCG ACC T-3'. The S1PR1 3'-UTR was cloned into the Ambion pMIR-REPORT ® miRNA Expression Reporter Vector (Thermo Fisher Scientific, Inc.), to yield pMIR-REPORT-S1PR1. Mutations were introduced in potential miR-133b binding sites using the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA, USA). Subsequently, the CNE2 cells were transfected with the pMIR-REPORT vectors containing either the wild-type or mutant S1PR1 3'-UTR, and with either the miR-133b mimic or NC plasmids, using Lipofectamine 2000, according to the manufacturer's protocol. The pRL-TK vector (Promega Corporation), encoding the Renilla luciferase gene, was used as an internal control to normalize the transfection efficiency. Luciferase values were determined using the Dual-Luciferase ® Reporter Assay system (Promega Corporation).
Statistical analysis. Data are presented as the mean ± standard error of the mean of ≥3 separate experiments. Statistical analyses were conducted using SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA). Differences between groups were analyzed using the Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results
miR-133b expression levels are reduced in NPC tissues.
In order to determine the expression levels of miR-133b, RT-qPCR was performed using 23 paired NPC tissues and adjacent normal tissues. The results demonstrated that miR-133b was 
miR-133b overexpression inhibits NPC cell proliferation.
In order to evaluate the biological function of miR-133b in NPC cell proliferation, miR-133b mimics or NC were transfected into CNE2 and HONE1 cells, and MTT and BrdU incorporation assays were conducted. Overexpression of miR-133b in the two cell lines was confirmed using RT-qPCR ( Fig. 2A  and B) . MTT assays demonstrated that cell growth was significantly inhibited by miR-133b overexpression (Fig. 2C  and D) . Consistent with this, BrdU assays showed that cell proliferation was markedly reduced in cells overexpressing miR-133b, as compared with those transfected with the NC (Fig. 2E and F) . Furthermore, the inhibition of endogenous miR-133b by transfection of the CNE2 and HONE1 cells with antisense oligonucleotides was shown to promote the growth and proliferation of the cells (Fig. 3) . These results indicate that miR-133b is able to inhibit the proliferation of NPC cells in vitro.
miR-133b inhibits the proliferation of NPC cells via downregulation of S1PR1. Potential direct targets of miR-133b were predicted using miWalk software, which revealed that S1PR1 harbors a potential miR-133b binding site (Fig. 4A) . Therefore, RT-qPCR and western blotting assays were conducted in order to investigate the effect of miR-133b on the protein expression levels of S1PR1. Notably, the protein expression levels of S1PR1 were reduced in the cells overexpressing miR-133b (Fig. 4B and C) . In addition, the protein expression levels of S1PR1 were markedly increased following inhibition of miR-133b with the antisense oligonucleotides ( Fig. 4D and E) . These results suggest that miR-133b may regulate S1PR1 expression at the translational level.
In order to confirm this, the full-length 3'-UTR of the human S1PR1 gene was cloned into the pMIR-REPORT vector downstream of the luciferase gene. Overexpression of the miR-133b mimics led to a significant reduction in luciferase activity when the reporter construct contained the S1PR1 3'-UTR (Fig. 4F) . However, mutation of the miR-133b binding site within the S1PR1 3'-UTR abolished this effect of miR-133b (Fig. 4F) . Consistent with this, it was observed that protein expression levels of S1PR1 were upregulated in the NPC tissues, as compared with the adjacent normal tissues (Fig. 4G) ; thus suggesting that S1PR1 is a direct target of miR-133b in NPC cells.
miR-133b regulates STAT3 signaling in NPC cells.
It has previously been shown that S1PR1 is crucial for persistent STAT3 activation in cancer cells (16) . Therefore, the present study examined STAT3 signaling pathways in the NPC cells following the overexpression or depletion of miR-133b. The protein expression levels of phosphorylated STAT3 were markedly reduced by miR-133b overexpression (Fig. 5A) . Concordantly, the mRNA expression levels of B-cell lymphoma-2, myeloid cell leukemia-1 and cellular inhibitor of apoptosis-2, which are downstream targets of STAT3 signaling, were also inhibited by miR-133b (Fig. 5B) . Conversely increased activation of these STAT3 signaling-associated proteins was observed in the cells following the depletion of miR-133b ( Fig. 5C  and D) . These results suggest that miR-133b may regulate the S1PR1-mediated activation of STAT3 signaling. 
A B C D Discussion
In the present study, miR-133b was shown to be expressed at significantly lower levels in NPC samples, as compared with adjacent normal tissue samples. However, the molecular events underlying the downregulation of miR-133b remain unclear.
Niederwieser et al (17) reported that high expression levels of DNA (cytosine-5-)-methyltransferase 3β were associated with differentially expressed miR-133b in older adults with primary, cytogenetically normal acute myeloid leukemia. Therefore, the present study hypothesized that epigenetic factors may contribute to the downregulation of miR-133b, although this requires further investigation in future studies. It is well known that each miRNA may regulate multiple gene targets. Previous studies have identified numerous target genes of miR-133b in a variety of tumor types; these genes include TBPL1, fibroblast growth factor receptor-1, specificity protein-1 and epidermal growth factor receptor (11, 12, (18) (19) (20) ; thus suggesting that the roles of miR-133b in tumorigenesis may be cell-or tissue-specific. The present study demonstrated that miR-133b overexpression inhibited, whereas its suppression increased, endogenous S1PR1 protein expression in NPC cells. Furthermore, luciferase reporter assays further identified S1PR1 as a direct target of miR-133b in NPC cells. Therefore, the results of the present study suggested that miR-133b may inhibit NPC cell proliferation, at least in part, by repressing S1PR1 expression.
Previous studies have reported upregulation of S1PR1, a G protein-coupled receptor for lysophospholipid sphingosine-1-phosphate (S1P), in STAT3-positive tumors (21-23). S1PR1-mediated STAT3 activation has been shown to occur in part by upregulation of the Janus Kinase 2 tyrosine kinase activity, whereas ablation of S1PR1 in tumor cells or immune cells inhibited tumor STAT3 activity (23) . Given that STAT3 has a crucial role in promoting the progression of human cancers (23, 24) , molecules or chemical compounds that target S1P/S1PR1 may be effective novel therapeutic agents for the prevention of malignant progression. Notably, in the present study, miR-133b was demonstrated to regulate STAT3 activation in NPC cells, further confirming a tumor suppressive role for miR-133b.
In conclusion, the present study demonstrated that miR-133b expression was downregulated in NPC tissues. Furthermore, miR-133b overexpression was able to inhibit the cell proliferation of NPC by reducing the protein expression levels of S1PR1. The results of the present study highlight an important role for miR-133b in NPC progression, which may aid the development of novel therapeutics for the treatment of patients with NPC.
